Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
NRBO NeuroBo Pharmaceuticals
1.450
-0.080-5.23%
Post Mkt Price
1.412
-0.038-2.65%
Symbol
NRBO
Company Name
NeuroBo Pharmaceuticals
Listing Date
08/05/2016
Establishment Date
2014
CEO
Dr. Ben Gil Price
Market
NASDAQ
Employees
11
Securities Type
DR
Fiscal Year Ends
12-31
Address
200 Berkeley Street,19th floor
City
Boston
Province
Massachusetts
Country
United States of America
Zip code
02116
Phone
1-857-702-9600
Profile
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. Its pipeline includes ANA001, a proprietary oral niclosamide formulation, Gemcabene, which is assessed as an acute indication for COVID-19, NB-01, a treatment for painful diabetic neuropathy, and NB-02, which has the potential to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases. The company was founded on October 30, 2014 and is headquartered in Boston, MA.
Company Overview
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. Its pipeline includes ANA001, a proprietary oral niclosamide formulation, Gemcabene, which is assessed as an acute indication for COVID-19, NB-01, a treatment for painful diabetic neuropathy, and NB-02, which has the potential to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases. The company was founded on October 30, 2014 and is headquartered in Boston, MA.
CEO: Dr. Ben Gil Price
Market: NASDAQ
Listing Date: 08/05/2016
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist